Marinus (MRNS) Receives a Buy from Mizuho Securities
Mizuho Securities analyst Difei Yang maintained a Buy rating on Marinus (MRNS) today and set a price target of $13. The company’s shares closed on Tuesday at $4.52.
According to TipRanks.com, Yang is a 5-star analyst with an average return of 17.8% and a 46.3% success rate. Yang covers the Healthcare sector, focusing on stocks such as Alder Biopharmaceuticals, Audentes Therapeutics, and Revance Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Marinus with a $16 average price target, a 254.0% upside from current levels. In a report issued on December 4, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $19 price target.
See today’s analyst top recommended stocks >>
Based on Marinus’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $11.11 million. In comparison, last year the company had a GAAP net loss of $4.17 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid.